Mutant p53 leads to low‐grade IFN‐I‐induced inflammation and impairs cGAS–STING signalling in mice
European Journal of Immunology · 2023
DOI: 10.1002/eji.202250211 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, 2023. Verfasst von Ziyi Qin und 13 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Genetics Laboratory of Aging and Tumor, Medical School, Kunming University of Science and Technology, Kunming, Yunnan, China. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Interferon Type I. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Type I interferons (IFN‐Is) are a class of proinflammatory cytokines produced in response to viruses and environmental stimulations, resulting in chronic inflammation and even carcinogenesis. However, the connection between IFN‐I and p53 mutation is poorly understood. Here, we investigated IFN‐I status in the context of mutant p53 (p53 N236S , p53S). We observed significant cytosolic double‐stranded DNA (dsDNA) derived from nuclear heterochromatin in p53S cells, along with an increased expression of IFN‐stimulated genes. Further study revealed that p53S promoted cyclic GMP‐AMP synthase (cGAS) and IFN‐regulatory factor 9 (IRF9) expression, thus activating the IFN‐I pathway. However, p53 S/S mice were more susceptible to herpes simplex virus 1 infection, and the cGAS–stimulator of IFN genes (STING) pathway showed a decline trend in p53S cells in response to poly(dA:dT) accompanied with decreased IFN‐β and IFN‐stimulated genes, whereas the IRF9 increased in response to IFN‐β stimulation. Our results illustrated the p53S mutation leads to low‐grade IFN‐I‐induced inflammation via consistent low activation of the cGAS–STING‐IFN‐I axis, and STAT1‐IRF9 pathway, therefore, impairs the protective cGAS–STING signalling and IFN‐I response encountered with exogenous DNA attack. These results suggested the dual molecular mechanisms of p53S mutation in inflammation regulation. Our results could be helping in further understanding of mutant p53 function in chronic inflammation and provide information for developing new therapeutic strategies for chronic inflammatory diseases or cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Genetics Laboratory of Aging and Tumor, Medical School, Kunming University of Science and Technology, Kunming, Yunnan, China.
- Guizhou Provincial Key Laboratory of Pathogenesis & Drug Development on Common Chronic Diseases, School of Basic Medicine, Guizhou Medical University, Guiyang, Guizhou, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Qin, Z., Liu, H., Sheng, Q., Dan, J., Wu, X., Li, H., Wang, L., Zhang, S., Yuan, C., Yuan, H., Wang, H., Zhou, R., Luo, Y., & Xie, X. (2023). Mutant p53 leads to low‐grade IFN‐I‐induced inflammation and impairs cGAS–STING signalling in mice. European Journal of Immunology. https://doi.org/10.1002/eji.202250211
Vancouver
Qin Z, Liu H, Sheng Q, Dan J, Wu X, Li H, et al. Mutant p53 leads to low‐grade IFN‐I‐induced inflammation and impairs cGAS–STING signalling in mice. European Journal of Immunology. 2023. doi:10.1002/eji.202250211
BibTeX
@article{Qin2023,
author = {Qin, Ziyi and Liu, Huan and Sheng, Qihuan and Dan, Juhua and Wu, Xiaoming and Li, Hao and Wang, Lulin and Zhang, Shuojie and Yuan, Chao and Yuan, Hongjun and Wang, Hui and Zhou, Ruoyu and Luo, Ying and Xie, Xiaoli},
title = {Mutant p53 leads to low‐grade IFN‐I‐induced inflammation and impairs cGAS–STING signalling in mice},
journal = {European Journal of Immunology},
year = {2023},
doi = {10.1002/eji.202250211}
}
EUVIMED